Boston Sci Sees Strong Data From Parkinson & #039;s Treatment Study

This study meets a new level of rigor in evaluating the effectiveness of a DBS system," Jerrold Vitek, MD, Phd, McKnight professor and chair, Department of Neurology, University of Minnesota Medical School and coordinating principal investigator for the INTREPID study, said in a release. "The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System." Boston Scientific received FDA approval for Vercise late last year. The device is different from other DBS offerings because it does not stem from pacemaker technology. Instead the device is derived from cochlear implant technology and is able to stimulate the area that needs stimulation in order to optimize the therapy. "Vercise is a rechargeable platform with a multiple independent control to offer more adaptable delivery of stimulation,” Boston Scientific’s President and CEO Michael Mahoney, said according to a Seeking Alpha Transcript.  
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news